Startseite>>Signaling Pathways>> Tyrosine Kinase>> Pyk2>>PF-4618433

PF-4618433

Katalog-Nr.GC61852

PF-4618433 ist ein potenter und selektiver PYK2-Inhibitor mit einem IC50-Wert von 637 nM.

Products are for research use only. Not for human use. We do not sell to patients.

PF-4618433 Chemische Struktur

Cas No.: 1166393-85-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
406,00 $
Auf Lager
5mg
369,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PF-4618433 is a potent and selective PYK2 inhibitor, with an IC50 of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration[1][2].

PF-4618433 (0.1-1.0 µM; 7 days) promotes osteogenesis of hMSC cultures. PF-4618433 increases in both alkaline phosphatase (ALP) activity and mineralization in a dependent manner[1].PF-4618433 (0.1-0.3 µM; 24 hours) enhances osteoblast proliferation[2].PF-4618433 (0.0125-0.3 µM; 14 or 21 days) enhances calcium deposition at the concentrations of 0.1 and 0.3 µM[2].

References:
[1]. Seungil H, et, al. Structural Characterization of Proline-Rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design. J Biol Chem. 2009 May 8; 284(19): 13193-201.
[2]. Sumana P, et, al. A Pyk2 Inhibitor Incorporated Into a PEGDA-gelatin Hydrogel Promotes Osteoblast Activity and Mineral Deposition. Biomed Mater. 2019 Feb 27; 14(2): 025015.

Bewertungen

Review for PF-4618433

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF-4618433

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.